20+ Leading Anti-CD20 Antibody Pipeline Companies are working to improve the Treatment Landscape

February 08 20:58 2023
20+ Leading Anti-CD20 Antibody Pipeline Companies are working to improve the Treatment Landscape

DelveInsight’s, “Anti-CD20 Antibody Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including Anti-CD20 Antibody clinical trials and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Anti-CD20 Antibody pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Anti-CD20 Antibody clinical trials studies, Anti-CD20 Antibody NDA approvals (if any), and product development activities comprising the technology, Anti-CD20 Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Anti-CD20 Antibody Pipeline Insight Report

 

  • Over 20+ Anti-CD20 Antibody companies are evaluating 20+ Anti-CD20 Antibody pipeline therapies in various stages of development, and their anticipated acceptance in the H Anti-CD20 Antibody market would significantly increase market revenue.

 

  • The leading Anti-CD20 Antibody Companies includes TG Therapeutics, Roche, Genmab/ Novartis, Biocad,  Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencor, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.

 

  • Promising Anti-CD20 Antibody Pipeline Therapies includes BI-1206 single agent dose escalation phase, rituximab [MabThera/Rituxan], Ofatumumab, Cyclophosphamide, Doxorubicin, HuMax-CD20, sargramostim, and others.

 

  • The Anti-CD20 Antibody companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD20 Antibody R&D. The Anti-CD20 Antibody pipeline therapies under development are focused on novel approaches to treat/improve Anti-CD20 Antibody.

 

 

To explore more information on the latest breakthroughs in the Anti-CD20 Antibody Pipeline treatment landscape of the report, click here @ Anti-CD20 Antibody Pipeline Outlook

 

Anti-CD20 Antibody Overview

 

CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells. This pattern, together with consistent and high levels of expression of CD20 on malignant B-cells, makes CD20 a therapeutic target. CD20 protein consists of four hydrophobic transmembrane domains, one intracellular and two extracellular domains (large and small loops) with both N- and C- termini residing within the cytosol. Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. Anti-CD20 monoclonal antibodies (mAbs) are used to achieve B cell depletion, and were initially developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Use of anti-CD20 therapy is vastly practiced to treat diseases with a high expression of CD20 antigen. Anti-CD20 antibodies are one of the most successful and effective antibodies which have employed in treatment of a wide range of diseases including cancer and immune related disorders.

 

Latest Breakthroughs/News of the Anti-CD20 Antibody Treatment Landscape

 

  • Aggrawal contends that there are no indications of a shrinking patient pool by citing the commercial success of competing MS treatments from Novartis (NVS) and Roche (OTCQX:RHHBY) in Q4 2022.

 

  • Ublituximab-xiiy was been given FDA approval for the treatment of individuals with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive illness. The medicine will be marketed as Briumvi. TG Therapeutics received authorization.

 

  • For patients with RMS, BRIUMVI is the first and only anti-CD20 monoclonal antibody that can be given in a one-hour infusion after the initial dosage. An thorough patient care programme is part of the launch of BRIUMVI and is intended to help patients throughout their therapeutic journey. On the website briumvi.com, you may find more details on the BRIUMVI Patient Support programme.

 

 

For further information, refer to the detailed Anti-CD20 Antibody Unmet Needs, Anti-CD20 Antibody Market Drivers, and Anti-CD20 Antibody Market Barriers, click here for Anti-CD20 Antibody Ongoing Clinical Trial Analysis

 

Anti-CD20 Antibody Emerging Drugs Profile

 

  • Ublituximab: TG therapeutics

Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell. TG Therapeutics completes the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody as a treatment for patients with chronic lymphocytic leukemia (CLL). The U.S. FDA previously granted Fast Track designation to the combination of ublituximab and umbralisib (U2) for the treatment of adult patients with CLL and orphan drug designation for ublituximab in combination with umbralisib for the treatment of CLL.

 

  • Glofitamab: Roche

Glofitamab (also known as RO7082859, RG6026) is an investigational, full-length, CD20- and CD3-targeting T-cell bispecific antibody that is designed to redirect T cells to engage and eliminate malignant B cells. Glofitamab is designed to bind to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies, while simultaneously binding to CD3, a component of the TCR on the surface of T cells. A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin is underway in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

 

Anti-CD20 Antibody Pipeline Therapeutic Assessment

There are approx. 20+ key companies which are developing the therapies for Anti-CD20 Antibody. The companies which have their Anti-CD20 Antibody drug candidates in the most advanced stage, i.e. Preregistration include, TG therapeutics.

 

Request a sample and discover the recent advances in Anti-CD20 Antibody Ongoing Clinical Trial Analysis and Medications, click here @ Anti-CD20 Antibody Treatment Landscape

 

Scope of the Anti-CD20 Antibody Pipeline Report

 

  • Coverage- Global
  • Anti-CD20 AntibodyCompanies- TG Therapeutics, Roche, Genmab/ Novartis, Biocad,  Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencor, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others
  • Anti-CD20 AntibodyPipeline Therapies- BI-1206 single agent dose escalation phase, rituximab [MabThera/Rituxan], Ofatumumab, Cyclophosphamide, Doxorubicin, HuMax-CD20, sargramostim, and others.
  • Anti-CD20 Antibody Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type

 

Dive deep into rich insights for drugs for Anti-CD20 Antibody Market Drivers and Anti-CD20 Antibody Market Barriers, click here @ Anti-CD20 Antibody Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Anti-CD20 Antibody: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anti-CD20 Antibody – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Anti-CD20 Antibody Collaboration Deals
  9. Late Stage Products (Preregistration) 
  10. Ublituximab: TG therapeutics
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II) 
  13. Odronextamab: Regeneron Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I)
  16. IGM 2323: IGM Biosciences
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Anti-CD20 Antibody Key Companies
  20. Anti-CD20 Antibody Key Products
  21. Anti-CD20 Antibody- Unmet Needs
  22. Anti-CD20 Antibody- Market Drivers and Barriers
  23. Anti-CD20 Antibody- Future Perspectives and Conclusion
  24. Anti-CD20 Antibody Analyst Views
  25. Anti-CD20 Antibody Key Companies
  26. Appendix

 

Got Queries? Find out the related information on Anti-CD20 Antibody Mergers and acquisitions, Anti-CD20 Antibody Licensing Activities @ Anti-CD20 Antibody Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services